The promise of protein-based and gene-based clinical markers in heart transplantation: From bench to bedside

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 3, 2006, Pages 136-143

  Mehra, Mandeep R ^a   Feller, Erika ^a   Rosenberg, Steve ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b XDx Inc   (United States)

Author keywords

Genomics; Graft function; Heart trandplantation; Proteomics; Rejection surveillance

Indexed keywords

ABC TRANSPORTER; ALLOGRAFT INFLAMMATORY FACTOR 1; BETA CRYSTALLIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CASPASE 8; CYTOCHROME P450 3A5; DIPEPTIDYL CARBOXYPEPTIDASE; GAMMA INTERFERON; GLYCOPROTEIN P; HEAT SHOCK PROTEIN 27; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MOLECULAR MARKER; PLASMINOGEN ACTIVATOR INHIBITOR 1; STEROID; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; TROPOMYOSIN; TROPONIN I; TROPONIN T; TSUKUBAENOLIDE; TUMOR NECROSIS FACTOR ALPHA; VITRONECTIN RECEPTOR;

ALLOIMMUNITY; BLOOD VESSEL INJURY; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG METABOLISM; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC VARIABILITY; GRAFT FAILURE; HEART CANCER; HEART FUNCTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFLAMMATION; MICROVASCULARIZATION; MOLECULAR DYNAMICS; NON INVASIVE MEASUREMENT; NONHUMAN; OUTCOMES RESEARCH; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOLOGICAL MARKERS; GENETIC MARKERS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; PROGNOSIS; PROTEINS;

EID: 33644587748     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0457     Document Type: Review

References (52)

1. Mehra MR et al. (2002) Anything but a biopsy: Noninvasive monitoring for cardiac allograft rejection. Curr Opin Cardiol 17: 131-136
2. Marboe CC et al. (2005) Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant 24 (Suppl): S219-226
3. Mehra MR (2005) The emergence of genomic and proteomic biomarkers in heart transplantation. J Heart Lung Transplant 24 (Suppl): S213-218
4. Awad MR et al. (2001) The effect of cytokine gene polymorphisms on pediatric heart allograft outcome. J Heart Lung Transplant 20: 625-630
5. Webber SA et al. (2002) Polymorphisms in cytokine genes do not predict progression to end-stage heart failure in children. Cardiol Young 12: 461-464
6. Abdallah AN et al. (1999) Analysis of the polymorphism of the tumour necrosis factor (TNF) gene and promoter and of circulating TNF-alpha levels in heart-transplant patients suffering or not suffering from severe rejection. Eur J Immunogenet 26: 249-255
7. Densem CG et al. (2001) Influence of tumor necrosis factor-alpha gene-308 polymorphism on the development of coronary vasculopathy after cardiac transplantation. J Heart Lung Transplant 20: 1265-1273
8. Borozdenkova S et al. (2001) Identification of ICAM1 polymorphism that is associated with protection from transplant associated vasculopathy after cardiac transplantation. Hum Immunol 62: 247-255
9. Pethig K et al. (2000) ACE-gene polymorphism is associated with the development of allograft vascular disease in heart transplant recipients. J Heart Lung Transplant 19: 1175-1182
10. Baan CC et al. (2000) Renal failure after clinical heart transplantation is associated with the TGF-β 1 codon 10 gene polymorphism. J Heart Lung Transplant 19: 866-872
11. Ojo AO et al. (2003) Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349: 931-940
12. Zheng H et al. (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3: 477-483
13. Zheng HX et al. (2004) The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis. Pediatr Transplant 8: 551-557
14. Holweg CT et al. (2004) Clinical impact of cytokine gene polymorphisms in heart and lung transplantation. J Heart Lung Transplant 23: 1017-1026
15. Christopher K et al. (2004) Modulation of gene expression by alloimmune networks following murine heart transplantation. Mol Genet Genomics 271: 687-696
16. Matsui Y et al. (2003) Identification of gene expression profile in tolerizing murine cardiac allograft by costimulatory blockade. Physiol Genomics 15: 199-208
17. DeFina R et al. (2003) Analysis of costimulation by 4-1 BBL, CD40L, and B7 in graft rejection by gene expression profiles. J Mol Med 81: 655-663
18. Shulzhenko N et al. (2001) Intragraft activation of genes encoding cytotoxic T lymphocyte effector molecules precedes the histological evidence of rejection in human cardiac transplantation. Transplantation 72: 1705-1708
19. de Groot-Kruseman HA et al (2003) Differential intragraft cytokine messenger RNA profiles during rejection and repair of clinical heart transplants. A longitudinal study. Transpl Int 16: 9-14
20. Fahmy NM et al. (2003) Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation 75: 72-78
21. Horwitz PA et al. (2004) Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression. Circulation 110: 3815-3821
22. Morgun A et al. (2003) Blood and intragraft CD27 gene expression in cardiac transplant recipients. Clin Immunol 107: 60-64
23. Schoels M et al. (2004) Detection of cardiac allograft rejection by real-time PCR analysis of circulating mononuclear cells. Clin Transplant 18: 513-517
24. Deng M et al. (2006) Non-invasive detection of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 6: 150-160
25. Starling R et al. (2005) The influence of corticosteroids on the alloimmune molecular signature for cardiac allograft rejection. J Heart Lung Transplant 24 (Suppl): S65-66
26. Re F et al. (1994) The type II "receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: Characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med 179: 739-743
27. Bernstein D et al. (2005) Gene expression profiling of cardiac allograft recipients with mild acute cellular rejection [abstract]. J Heart Lung Transplant 24 (Suppl): S65
28. Evans RW et al. (2005) The economic implications of noninvasive molecular testing for cardiac allograft rejection. Am J Transplant 5: 1553-1558
29. Borozdenkova S et al. (2004) Use of proteomics to discover novel markers of cardiac allograft rejection. J Proteome Res 3: 282-288
30. De Souza AI et al. (2005) Heat shock protein 27 is associated with freedom from graft vasculopathy after human cardiac transplantation. Circ Res 97: 192-198
31. Tambur AR et al. (2000) Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Transplantation 70: 1055-1059
32. Kobashigawa JA et al. (1996) Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Circulation 94 (Suppl): II294-II297
33. Taylor DO et al. (2000) Allograft coronary artery disease: Clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 19: 518-521
34. Thompson JS et al. (2000) The influence of conventional and cross-reactive group HLA matching on cardiac transplant outcome: An analysis from the United Network of Organ Sharing Scientific Registry. Transplantation 69: 2178-2186
35. John R et al. (2000) Impact of current management practices on early and late death in more than 500 consecutive cardiac transplant recipients. Ann Surg 232: 302-311
36. Itescu S et al. (1998) An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients. Lancet 352: 263-270
37. Mehra MR et al. (2004) The impact of mode of donor brain death on cardiac allograft vasculopathy: An intravascular ultrasound study. J Am Coll Cardiol 43: 806-810
38. Yamani MH et al. (2002) Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. J Am Coll Cardiol 39: 970-977
39. Taegtmeyer AB et al. (2004) Reduced incidence of hypertension after heterotopic cardiac transplantation compared with orthotopic cardiac transplantation: Evidence that excision of the native heart contributes to post-transplant hypertension. J Am Coll Cardiol 44: 1254-1260
40. Labarrere CA et al. (2000) Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. JAMA 284, 457-464
41. Benza RL et al. (1998) Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease. Circulation 98: 2248-2254
42. Labarrere CA et al. (1995) Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. N Engl J Med 333: 1111-1116
43. Yamani MH et al. (2002) Acute vascular rejection is associated with up-regulation of vitronectin receptor (αvβ3), increased expression of tissue factor, and activation of the extracellular matrix metalloproteinase induction system. J Heart Lung Transplant 21: 983-989
44. Ventura HO and Mehra MR (2003) C-Reactive protein and cardiac allograft vasculopathy is inflammation the critical link? J Am Coll Cardiol 42: 483-485
45. Eisenberg MS et al (2000) Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 102: 2100-2104
46. Pethig K et al. (2000) Systemic inflammatory response in cardiac allograft vasculopathy: High-sensitivity C-reactive protein is associated with progressive luminal obstruction. Circulation 102 (Suppl 3): III233-III236
47. Labarrere CA et al. (2002) C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: A prospective study. Lancet 360: 1462-1467
48. Hognestad A et al. (2003) Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. J An Coll Cardiol 42: 477-482
49. Autieri MV et al. (2002) Allograft inflammatory factor-1 expression correlates with cardiac rejection and development of cardiac allograft vasculopathy. Circulation 106: 2218-2223
50. Mehra MR et al. (2004) Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. Am J Cardiol 94: 454-458
51. Mehra MR et al. (2004) Molecular pathways of cardiac allograft dysfunction independent of acute cellular rejection [abstract]. J Am Coll Cardiol 43 (Suppl A): 1051-1127: 175A
52. Ogawa T et al. Neuroendocrine profiling of humans receiving cardiac allografts. J Heart Lung Transplant 24: 1046-1054